Cheng Yalan, Wang Qingjie, Chen Lanlan, Zhou Jibin
Eye Center, Ninghai First Hospital Ningbo 315600, Zhejiang, China.
Eye Center, Ninghai Maternal and Child Health Hospital Ningbo 315600, Zhejiang, China.
Am J Transl Res. 2025 Jun 15;17(6):4590-4600. doi: 10.62347/IOVP2431. eCollection 2025.
To evaluate the clinical efficacy of Conbercept combined with retinal photocoagulation in patients with proliferative diabetic retinopathy (PDR) and its effect on visual acuity and related outcomes.
This retrospective study included 120 PDR patients treated between January 2019 and January 2021. Based on treatment modality, patients were assigned to a study group (SG, n=60; Conbercept combined with retinal photocoagulation) or a control group (CG, n=60; retinal photocoagulation alone). Surgical data, best-corrected visual acuity (BCVA), central macular thickness (CMT), frequency of Conbercept injections, incidence of postoperative complications, quality of life (QoL) scores, and the need for additional pan-retinal photocoagulation (PRP) were compared between the two groups. Multivariate logistic regression was performed to identify independent risk factors associated with surgical complications.
Compared to the CG, the SG demonstrated significantly reduced intraoperative bleeding and greater improvements in BCVA and CMT from 1-48 months postoperatively (<0.05). The SG required fewer additional PRP sessions at 6 months postoperatively (<0.05), and demonstrated significantly lower rates of vitreous hemorrhage and macular edema recurrence (<0.05). QoL scores were significantly higher in the SG at the 48-month follow-up (<0.05). Logistic regression analysis identified age ≥60 years, disease duration ≥15 years, baseline HbA1c ≥8.5%, surgical duration ≥90 minutes, intraoperative bleeding ≥2 mL, and lack of early anti-VEGF therapy as independent risk factors for postoperative complications (<0.05).
The combination of Conbercept with retinal photocoagulation significantly improved visual outcomes and reduced postoperative complications in PDR patients, particularly beneficial for patients with advanced age, prolonged disease duration, elevated HbA1c, extended surgical duration, or intraoperative bleeding.
评估康柏西普联合视网膜光凝治疗增殖性糖尿病视网膜病变（PDR）患者的临床疗效及其对视力和相关结局的影响。
这项回顾性研究纳入了2019年1月至2021年1月期间接受治疗的120例PDR患者。根据治疗方式，将患者分为研究组（SG，n = 60；康柏西普联合视网膜光凝）或对照组（CG，n = 60；单纯视网膜光凝）。比较两组的手术数据、最佳矫正视力（BCVA）、中心黄斑厚度（CMT）、康柏西普注射频率、术后并发症发生率、生活质量（QoL）评分以及额外进行全视网膜光凝（PRP）的必要性。进行多因素逻辑回归分析以确定与手术并发症相关的独立危险因素。
与CG相比，SG术中出血明显减少，术后1至48个月的BCVA和CMT改善更大（<0.05）。SG术后6个月需要额外进行PRP的次数更少（<0.05），玻璃体出血和黄斑水肿复发率显著更低（<0.05）。在48个月随访时，SG的QoL评分显著更高（<0.05）。逻辑回归分析确定年龄≥60岁、病程≥15年、基线糖化血红蛋白（HbA1c）≥8.5%、手术时间≥90分钟、术中出血≥2 mL以及缺乏早期抗血管内皮生长因子（VEGF）治疗是术后并发症的独立危险因素（<0.05）。
康柏西普联合视网膜光凝显著改善了PDR患者的视力结局并减少了术后并发症，对年龄较大、病程较长、HbA1c升高、手术时间延长或术中出血的患者尤其有益。
